Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-fluoroglutamine PET Imaging in Pulmonary Arterial Hypertension
NCT05452889Phase 1Recruiting
- Start
- Jul 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-(2S,4R)4-fluoroglutamine in pulmonary arterial hypertension (PAH) and scleroderma. Primary endpoint: Standardized Uptake Value at 90 minutes. Started Jul 2022; status: recruiting.
02
Drugs
18F-(2S,4R)4-fluoroglutamine
03
Conditions
pulmonary arterial hypertension (PAH)scleroderma
Beyond the preview
Go deeper on NCT05452889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05452889.